Trends in contrast media research

Investigative Radiology

Volumn 36, Issue 12, 2001, Pages 688-691

  Runge, V M ^a  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; IODINATED CONTRAST MEDIUM;

COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; EDITORIAL; MEDICAL LITERATURE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RESEARCH; ULTRASOUND;

EID: 0035660647     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004424-200112000-00002     Document Type: Editorial

References (63)

1. Stability of MRI paramagnetic contrast media: A proton relaxometric protocol for transmetallation assessment
2. In vitro evaluation of intravascular stent artifacts in three-dimensional MR angiography
3. Contrast-enhanced peripheral MR angiography from the abdominal aorta to the pedal arteries: Combined dynamic two-dimensional and bolus-chase three-dimensional acquisitions
4. MRI techniques in early stages of cartilage disease
5. Detection of intracranial metastases: A multicenter, intrapatient comparison of gadobenate dimeglumine-enhanced MRI with routinely used contrast agents at equal dosage
6. MR imaging of the small bowel with a true-FISP sequence after enteroclysis with water solution
7. Hepatocellular carcinoma: Correlation between gadobenate dimeglumine-enhanced MRI and pathologic findings
8. Characterization of ultrasmall, paramagnetic magnetite particles as superparamagnetic contrast agents in MRI
9. Magnetic resonance imaging in patients with central nervous system pathology: A comparison of OptiMARK (Gd-DTPA-BMEA) and Magnevist (Gd-DTPA)
10. Mechanical delivery of aerosolized gadolinium-DTPA for pulmonary ventilation assessment in MR imaging
11. Development of a tumortargeting MR contrast agent using the high-affinity folate receptor: Work in progress
12. A minimally invasive method for creating coronary stenosis in a swine model for MRI and SPECT imaging
13. Preoperative contrast-enhanced MRI of the parathyroid glands in hyperparathyroidism
14. Synthesis, characterization, and imaging performance of a new class of macrocyclic hepatobiliary MR contrast agents
15. Safety and efficacy of Omniscan (gadodiamide injection) at 0.1 mmol/kg for MRI in infants younger than 6 months of age: Phase III open multicenter study
16. Contrast-reduced imaging of tissue concentration and arterial level (CRITICAL) for assessment of cerebral hemodynamics in acute stroke by magnetic resonance
17. MRI contrast enhancement of necrosis by MP-2269 and gadophrin-2 in a rat model of liver infarction
18. A clinical comparison of the safety and efficacy of MultiHance (gadobenate dimeglumine) and Omniscan (Gadodiamide) in magnetic resonance imaging in patients with central nervous system pathology
19. Magnetic resonance colonography and virtual magnetic resonance colonoscopy with the 1.0-T system: A feasibility study
20. Detection of experimental hepatic tumors using long circulating superparamagnetic particles
21. Superparamagnetic iron oxide-enhanced MRI of atherosclerotic plaques in Watanabe hereditable hyperlipidemic rabbits
22. In vivo microscopic evaluation of the microvascular behavior of FITC-labeled macromolecular MR contrast agents in the hamster skinfold chamber
23. Hydro-MRI in Crohn's disease: Appraisal of disease activity
24. Potential of Gd-DTPA-mannan liposome particles as a pulmonary perfusion MRI contrast agent: An initial animal study
25. Pharmacokinetics of 1 M gadobutrol in patients with chronic renal failure
26. 3+ complexes with slowly exchanging bound-water molecules may offer advantages in the design of responsive MR agents
27. Timing of the hepatic arterial phase during contrast-enhanced computed tomography of the liver: Assessment of normal values in 25 volunteers
28. Preclinical profile of the monodisperse iodinated macromolecular blood pool agent P743
29. Characterization of continuously extruded iopromide-carrying liposomes for computed tomography blood-pool imaging
30. A review of contrast media research in 1999-2000
31. Comparison of double-contrast CT arthrography image quality with nonionic contrast agents: Isotonic dimeric iodixanol 270 mg I/mL and monomeric iohexol 300 mg I/mL
32. Clinical safety of SonoVue, a new contrast agent for ultrasound imaging, in healthy volunteers and in patients with chronic obstructive pulmonary disease
33. Pulse inversion imaging of liver blood flow: Improved method for characterizing focal masses with microbubble contrast
34. Infusion versus bolus of an ultrasound contrast agent: In vivo dose-response measurements of BR1
35. Influence of bubble size distribution on the echogenicity of ultrasound contrast agents: A study of SonoVue
36. Enhanced detection of blood flow in the normal canine prostate using an ultrasound contrast agent
37. First experiences in using a new ultrasound mode and ultrasound contrast agent in the diagnosis of blunt renal trauma: A feasibility study in an animal model
38. Molecular imaging of stretch-induced tissue factor expression in carotid arteries with intravascular ultrasound
39. Evaluation of contrastenhanced color Doppler ultrasound for the quantification of angiogenesis in vivo
40. Human pharmacokinetics and safety evaluation of SonoVue, a new contrast agent for ultrasound imaging
41. Assessment of the vascularization of neuroendocrine tumors by stimulated acoustic emission of SH U 508A ultrasound contrast agent and color or power Doppler sonography
42. The use of a thrombusspecific ultrasound contrast agent to detect thrombus in arteriovenous fistulae
43. Iomeprol: Current and future profile of a radiocontrast agent
44. Clinical experience with iomeprol in myelography and myelo-CT: Clinical pharmacology and double-blind comparisons with iopamidol, iohexol, and iotrolan
45. Pharmacokinetics and safety of iomeprol in healthy volunteers and in patients with renal impairment or end-stage renal disease requiring hemodialysis
46. Safety and pharmacokinetics of a new liposomal liver-specific contrast agent for CT: Results of clinical testing in nonpatient volunteers
47. Acute and subacute physiological and histological studies of the central nervous system after intrathecal gadolinium injection in the anesthetized rat
48. Review of studies establishing the aging male spontaneously hypertensive rat as a detector and quantifier of the kidney toxicity of radiocontrast media and other chemicals
49. Neurotolerability of contrast agents in rats with brain ischemia induced by transient middle cerebral artery occlusion: EEG evaluation
50. Hemostatic effect of glue-lipiodol mixture plugged in the needle tract after renal biopsies in a highrisk, anticoagulated rabbit model
51. Evaluation of breath-hold contrast-enhanced 3D magnetic resonance angiography technique for imaging visceral abdominal arteries and veins
52. Long-term effect of irradiation on lymph node uptake of interstitially delivered nanoparticulate contrast media
53. Novel receptor-targeted fluorescent contrast agents for in vivo tumor imaging
54. Polyiodinated triglyceride lipid emulsions for use as hepatoselective contrast agents in CT: Effects of physicochemical properties on biodistribution and imaging profiles
55. Pharmacokinetics of three gadolinium chelates with different molecular sizes shortly after intravenous injection in rabbits: Relevance to MR angiography
56. In vitro model of the human liver parenchyma to study hepatotoxic side effects by Dy-EOB-DTPA
57. Prevention of the hemodynamic effects of iopromide-carrying liposomes in rats and pigs
58. Hemodynamic effect of iodinated high-viscosity contrast medium in the rat kidney: A diffusion-weighted MRI feasibility study
59. Hepatocyte targeting with Gd-EOB-DTPA: Potential application for gene therapy
60. Pilot MR evaluation of pharmacokinetics and relaxivity of specific blood pool agents for MR angiography
61. Time course of nodal enhancement with CT x-ray nanoparticle contrast agents: Effect of particle size and chemical structure
62. Nitric oxide protects against contrast media-increased pulmonary vascular permeability in rats
63. Contrast medium-induced pulmonary vascular hyperpermeability is aggravated in a rat climacterium model